Terms: = Lymphoma AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
61 results:
1. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract] [Full Text] [Related]
2. Therapeutic Effects of Saponins for the Prevention and treatment of Cancer by Ameliorating Inflammation and Angiogenesis and Inducing Antioxidant and Apoptotic Effects in Human Cells.
Khan MI; Karima G; Khan MZ; Shin JH; Kim JD
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142578
[TBL] [Abstract] [Full Text] [Related]
3. Anti-tumour effect of in situ vaccines combined with vegfr inhibitors in the treatment of metastatic cervical cancer.
Liu L; Cai L; Du X; Zhao J; Zhao Y; Zou C; Yu S; Zhang C; Ye P; Su X; Yan X; Li W
Int Immunopharmacol; 2021 Dec; 101(Pt B):108302. PubMed ID: 34717193
[TBL] [Abstract] [Full Text] [Related]
4. Angiogenesis' related genetic variants alter clinical features and prognosis of diffuse large B-cell lymphoma patients.
Brito ABC; Delamain MT; Fanelli MF; Soares FA; de Souza CA; Vassallo J; Lima CSP
Tumour Biol; 2021; 43(1):129-140. PubMed ID: 34219681
[TBL] [Abstract] [Full Text] [Related]
5. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Escudero-Vilaplana V; Collado-Borrell R; Del Monte-Millán M; Hoyo-Muñoz A; Gómez Martínez-Sagrera P; Revuelta-Herrero JL; Marzal-Alfaro B; Gonzalez-Haba E; López-Tarruella Cobo S; Jerez Gilarranz Y; Herranz A; Sanjurjo M; Martin M
Support Care Cancer; 2021 Aug; 29(8):4673-4681. PubMed ID: 33506273
[TBL] [Abstract] [Full Text] [Related]
6. vegfr2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Watanabe H; Ichihara E; Kayatani H; Makimoto G; Ninomiya K; Nishii K; Higo H; Ando C; Okawa S; Nakasuka T; Kano H; Hara N; Hirabae A; Kato Y; Ninomiya T; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Cancer Sci; 2021 May; 112(5):1853-1864. PubMed ID: 33410241
[TBL] [Abstract] [Full Text] [Related]
7. Tim-3 promotes tube formation and decreases tight junction formation in vascular endothelial cells.
Cong Y; Wang X; Wang S; Qiao G; Li Y; Cao J; Jiang W; Cui Y
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33015716
[TBL] [Abstract] [Full Text] [Related]
8. Apatinib, a novel vegfr-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.
Li L; Kong F; Zhang L; Li X; Fu X; Wang X; Wu J; Zhang F; Ren L; Zhang M
Invest New Drugs; 2020 Dec; 38(6):1847-1853. PubMed ID: 32363427
[TBL] [Abstract] [Full Text] [Related]
9. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
[TBL] [Abstract] [Full Text] [Related]
10.
Lou L; Chen G; Zhong B; Liu F
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31383785
[No Abstract] [Full Text] [Related]
11. Properties of FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
[TBL] [Abstract] [Full Text] [Related]
12. Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors.
Sun Y; Yang L; Hao X; Liu Y; Zhang J; Ning Z; Shi Y
J Hematol Oncol; 2019 Jan; 12(1):9. PubMed ID: 30642372
[TBL] [Abstract] [Full Text] [Related]
13. Dysfunctional endothelial progenitor cells in patients with Hodgkin's lymphoma in complete remission.
Wiessman M; Leshem D; Yeshurun M; Yavin H; Iakobishvilli Z; Raanani P; Kornowski R; Lev EI; Vaturi M
Cancer Med; 2019 Jan; 8(1):305-310. PubMed ID: 30549248
[TBL] [Abstract] [Full Text] [Related]
14. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract] [Full Text] [Related]
15. CS2164 exerts an antitumor effect against human Non-Hodgkin's lymphomas in vitro and in vivo.
Deng M; Shi Y; Chen K; Zhao H; Wang Y; Xie S; Zhao J; Luo Y; Fang Z; Fan Y; Xu B
Exp Cell Res; 2018 Aug; 369(2):356-362. PubMed ID: 29864401
[TBL] [Abstract] [Full Text] [Related]
16. [A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation
Treated with Anlotinib].
Su Y; Meng Z; Xu X; Wang X; Zuo R; Hou Y; Li K; Chen P
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):428-430. PubMed ID: 29764596
[TBL] [Abstract] [Full Text] [Related]
17. Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated vegfr2 Receptors as Modulators of Antiangiogenic Therapies.
Toledo RA; Garralda E; Mitsi M; Pons T; Monsech J; Vega E; Otero Á; Albarran MI; Baños N; Durán Y; Bonilla V; Sarno F; Camacho-Artacho M; Sanchez-Perez T; Perea S; Álvarez R; De Martino A; Lietha D; Blanco-Aparicio C; Cubillo A; Domínguez O; Martínez-Torrecuadrada JL; Hidalgo M
Clin Cancer Res; 2018 Aug; 24(15):3550-3559. PubMed ID: 29588308
[No Abstract] [Full Text] [Related]
18. Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia.
Deng M; Zha J; Jiang Z; Jia X; Shi Y; Li P; Chen XL; Fang Z; Du Z; Xu B
J Transl Med; 2018 Feb; 16(1):47. PubMed ID: 29490645
[TBL] [Abstract] [Full Text] [Related]
19. Synergistic Effect of TPD7 and Berberine against Leukemia Jurkat Cell Growth through Regulating Ephrin-B2 Signaling.
Ma W; Zhu M; Yang L; Yang T; Zhang Y
Phytother Res; 2017 Sep; 31(9):1392-1399. PubMed ID: 28703366
[TBL] [Abstract] [Full Text] [Related]
20. Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes.
Fleuren EDG; Vlenterie M; van der Graaf WTA; Hillebrandt-Roeffen MHS; Blackburn J; Ma X; Chan H; Magias MC; van Erp A; van Houdt L; Cebeci SAS; van de Ven A; Flucke UE; Heyer EE; Thomas DM; Lord CJ; Marini KD; Vaghjiani V; Mercer TR; Cain JE; Wu J; Versleijen-Jonkers YMH; Daly RJ
Cancer Res; 2017 Aug; 77(16):4279-4292. PubMed ID: 28634201
[TBL] [Abstract] [Full Text] [Related]
[Next]
